Test for sepsis therapy proves its worth:
This article was originally published in Clinica
A dry chemistry test developed by Cardiovascular Diagnostics has proved its viability in evaluating the effect of Eli Lilly's therapeutic anticoagulant on patients with sepsis. The next step will be to carry out further testing of patient samples in order to define the test parameters. As a result, Cardiovascular Diagnostics expects to alter the formulation of the test. Sepsis has a mortality rate of 30-50% and is caused by pathogens circulating in the blood which results in serious complications such as organ failure.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.